Bone structural characteristics and response to bisphosphonate treatment in children with Hajdu-Cheney Syndrome.
Conclusions: Increased bone resorption and low cortical thickness are consistent with the effect of activating NOTCH2 mutations, which stimulate osteoclastogenesis. The increase in lumbar spine bone density and radial cortical thickness and density by BP therapy provides evidence of beneficial treatment effects in children with HJCYS. PMID: 28938420 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - September 8, 2017 Category: Endocrinology Authors: Sakka S, Gafni RI, Davies JH, Clarke B, Tebben P, Samuels M, Saraff V, Klaushofer K, Fratzl-Zelman N, Roschger P, Rauch F, Högler W Tags: J Clin Endocrinol Metab Source Type: research

Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.
Authors: Dragomir A, Rocha J, Vanhuyse M, Cury FL, Kassouf W, Hu J, Aprikian AG Abstract INTRODUCTION: Since just after the year 2000 in Quebec, the management of metastatic castration-resistant prostate cancer (mcrpc) has evolved considerably, with the inclusion of docetaxel-based chemotherapy, bone-targeted therapies (zoledronic acid and denosumab), and more recently, abiraterone, enzalutamide, and cabazitaxel for docetaxel-refractory patients. In the present study, we aimed to analyze contemporary mcrpc management patterns and therapy utilization trends in Quebec. METHODS: The study cohort consisted of patie...
Source: Current Oncology - September 7, 2017 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Influence of Japanese Regulatory Action on Denosumab-Related Hypocalcemia Using Japanese Adverse Drug Event Report Database.
This study suggests that the regulatory action against hypocalcemia in DEN effectively decreased hypocalcemia signal. Further studies using medical information databases are needed to confirm this result. PMID: 28867727 [PubMed - in process] (Source: Biological and Pharmaceutical Bulletin)
Source: Biological and Pharmaceutical Bulletin - September 6, 2017 Category: Drugs & Pharmacology Authors: Takeyama M, Sai K, Imatoh T, Segawa K, Hirasawa N, Saito Y Tags: Biol Pharm Bull Source Type: research

Bilateral retrobulbar optic neuropathy as the only sign of zoledronic acid toxicity
In conclusion, patients treated with bisphosphonates should be informed about the possibility of ocular side-effects, and ophthalmologists should be consider discontinuing the drug. (Source: Journal of Clinical Neuroscience)
Source: Journal of Clinical Neuroscience - September 5, 2017 Category: Neuroscience Source Type: research

Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk
ConclusionsAfter first-line BP therapy in postmenopausal women with osteoporosis, the risk of new clinical fractures was 40% higher in subjects who took a bisphosphonate drug holiday. (Source: Osteoporosis International)
Source: Osteoporosis International - September 5, 2017 Category: Orthopaedics Source Type: research

Chronic treatment with Zoledronic Acid increases inflammatory markers in periodontium of rats
Abstract BackgroundBisphosphonates (BF) rises proinflammatory markers and irreversibly binds to bone. Chronically BF can lead to an inflammatory status and can increase the local oxidative stress in periodontium. Therefore, the objective of this study was evaluated if the chronic infusion of Zoledronic Acid (ZA) increases inflammatory markers in periodontium of rats. Methods and resultsChronically infusion therapy was performed with ZA (0.04, 0.2 or 1 mg/kg or saline) by four doses in over a 70‐day period to analysis periodontium of the first right inferior molar using histologic, histochemical (toluidine blue) and immun...
Source: Journal of Oral Pathology and Medicine - September 2, 2017 Category: Pathology Authors: Paulo Goberl ânio de Barros Silva, Antonio Ernando Carlos Ferreira Junior, Camila Carvalho de Oliveira, Luiz André Cavalcante Brizeno, Deysi Viviana Tenazoa Wong, Roberto César Pereira Lima Júnior, Fabrício Bitú Sousa, Mário Rogério Lima Mota, Ana Tags: Original Article Source Type: research

Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
We conducted a meta-analysis based on eligible studies to assess the efficacy and safety of zoledronic acid treatment for postmenopausal women with osteoporosis. PubMed, Web of Science, and Embase were searched for eligible studies that assessed the efficacy of zoledronic acid in the prevention of fractures among postmenopausal women with osteoporosis. The primary outcomes were new vertebral fracture, nonvertebral fracture, and hip fracture. Secondary outcomes were bone mineral density (BMD) and safety outcomes. A fixed-effect or random-effect model was used to pool the estimates according to the heterogeneity among the in...
Source: American Journal of Therapeutics - September 1, 2017 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research

Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid
Conclusions Bone-only MBC patients are more likely to experience an SSE even after treatment with ZA. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - September 1, 2017 Category: Cancer & Oncology Source Type: research

Effect of zoledronic acid on lumbar spinal fusion in osteoporotic patients
ConclusionsZoledronic acid accelerates spinal fusion, shortens the time of fusion without changing fusion rate, and also decreases the risk of adjacent vertebral compressing fracture and the rate of pedicle screw loosening, resulting in the improvement of clinical outcomes and quality of life. (Source: European Spine Journal)
Source: European Spine Journal - September 1, 2017 Category: Orthopaedics Source Type: research

High-activity chitosan/nano hydroxyapatite/zoledronic acid scaffolds for simultaneous tumor inhibition, bone repair and infection eradication
Publication date: 1 January 2018 Source:Materials Science and Engineering: C, Volume 82 Author(s): Yao Lu, Mei Li, Lihua Li, Shuzhen Wei, Xiaoming Hu, Xiaolan Wang, Guiqiu Shan, Yu Zhang, Hong Xia, Qingshui Yin Implanted biomaterials combined tumor inhibition and bone repair property are urgently needed to address the huge bone destruction and the high local recurrence following primary surgery in bone tumor therapy. In this work, a high-activity chitosan/nano hydroxyapatite (CS/nHA) scaffold containing zoledronic acid (CS/nHA/Zol) was prepared with a facile method. The prepared CS/nHA/Zol scaffolds exhibited excellent tu...
Source: Materials Science and Engineering: C - September 1, 2017 Category: Materials Science Source Type: research

Clinical Efficacy Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in the Treatment and Prevention of Osteoporotic Vertebral Compression Fractures.
CONCLUSIONS: Results of this study indicate that the clinical efficacy of PKP combined with aclasta in the treatment and prevention of OVCF is significant. PMID: 28829670 [PubMed - as supplied by publisher] (Source: Journal of Investigative Surgery)
Source: Journal of Investigative Surgery - August 24, 2017 Category: Surgery Tags: J Invest Surg Source Type: research

Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique
A novel zoledronic acid (ZL) derivative, 3‐(2‐ethyl‐4‐methyi‐1H‐imidazole‐1‐yl)‐1‐hydroxy‐1‐phosphonopropyl phosphonic acid (EMIHPBP), was synthesized, characterized, and successfully radiolabeled with 99mTc. The in vivo biodistribution of 99mTc‐EMIHPBP was investigated and compared with the previously reported zoledronate derivatives aiming to formulate a novel zoledronate derivative with a high‐potential uptake to bone as a promising antiosteoporotic candidate. To further evaluate the bone uptake efficiency, the pharmacokinetics of 99mTc‐EMIHPBP was investigated and showed that maximum conce...
Source: Journal of Labelled Compounds and Radiopharmaceuticals - August 24, 2017 Category: Biochemistry Authors: H.A. Motaleb, Ismail Taha Ibrahim, M. El ‐Tawoosy, M.I. Mohamed Tags: RESEARCH ARTICLE Source Type: research

Zoledronic acid, an FPPS inhibitor, ameliorates liver steatosis through inhibiting hepatic de novo lipogenesis.
In conclusion, our data provide a novel application of ZA in improving hepatic steatosis. PMID: 28843826 [PubMed - as supplied by publisher] (Source: European Journal of Pharmacology)
Source: European Journal of Pharmacology - August 23, 2017 Category: Drugs & Pharmacology Authors: Tang Q, Jiang S, Jia W, Shen D, Qiu Y, Zhao Y, Xue B, Li C Tags: Eur J Pharmacol Source Type: research

Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: A meta-analysis from randomized controlled trails
This meta-analysis aimed to assess the efficiency of intravenous administration of zoledronic acid on reducing femoral periprosthetic bone mineral density loss in patients undergoing primary total hip arthroplasty (THA). (Source: International Journal of Surgery)
Source: International Journal of Surgery - August 18, 2017 Category: Surgery Authors: Jian Gao, Chong Gao, Hui Li, Guo-sheng Wang, Chang Xu, Jian Ran Tags: Review Source Type: research

Compromised socket healing in rats under zoledronic acid treatment after extraction of teeth with periodontitis: insights into the pathogenesis of osteonecrosis of the jaws
Osteonecrosis of the jaws (ONJ) is a rare but severe complication of antiresorptive medications, such as bisphosphonates. To gain insight into the role of tooth extraction and dental disease in ONJ pathogenesis, this study investigated socket healing after extraction of healthy or periodontally compromised teeth in rats treated with zoledronic acid (ZA). (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - August 17, 2017 Category: ENT & OMF Authors: A. SOUNDIA, D. HADAYA, N. EFSANDI, I. GKOUVERIS, R. CHRISTENSEN, S.M. DRY, O. BEZOUGLAIA, F.Q. PIRIH, N. NIKITAKIS, T. AGHALOO, S. TETRADIS Source Type: research

Lipid Bilayer-Gated Mesoporous Silica Nanocarriers for Tumor-Targeted Delivery of Zoledronic Acid in Vivo
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.7b00519 (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - August 10, 2017 Category: Drugs & Pharmacology Authors: Diti Desai, Jixi Zhang, Jouko Sandholm, Jaakko Lehtima ̈ki, Tove Grönroos, Johanna Tuomela and Jessica M. Rosenholm Source Type: research

Bilateral Acute Anterior Uveitis and Conjunctivitis following Intravenous Zoledronic Acid.
We report a patient of osteoporosis who was treated with zoledronic acid infusion. He developed ocular pain, redness, watering, photophobia and swelling of both the eyes. He was diagnosed with acute anterior uveitis and conjunctivitis and treated with topical 1% prednisolone acetate and 1% atropine sulphate. The signs of inflammation abated by one week and the steroids were tapered over the next six weeks. There were no further recurrences. Patients must be educated about the ocular side-effects of bisphosphonate therapy, monitored closely after intravenous infusion and advised to seek ophthalmic consultation promptly if a...
Source: Journal of the Association of Physicians of India - August 10, 2017 Category: General Medicine Tags: J Assoc Physicians India Source Type: research

Drug-Induced Autoimmune Hepatitis following Treatment with Zoledronic Acid
Adverse drug reactions are among the most frequent side effects of synthetic and complementary alternative drugs and represent the premier causes of license revocations and acute liver failure. Drug-induced liver injury can resemble literally any other genuine liver disease and usually responds well to drug dechallenge. However, in some cases autoimmune-like hepatitis can evolve, requiring short- and sometimes long-term immunosuppression. Here, we present the hitherto first case of autoimmune-like hepatitis following treatment with zoledronic acid.Case Rep Gastroenterol 2017;11:440 –445 (Source: Case Reports in Gastroenterology)
Source: Case Reports in Gastroenterology - August 8, 2017 Category: Gastroenterology Source Type: research

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease
Abstract Multiple myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of plasma cells in the bone marrow. More than 80% of patients with MM display evidence of myeloma bone disease (MBD), characterised by the formation of osteolytic lesions throughout the axial and appendicular skeleton. MBD significantly increases the risk of skeletal‐related events such as pathologic fracture, spinal cord compression and hypercalcaemia. MBD is the result of MM plasma cells‐mediated activation of osteoclast activity and suppression of osteoblast activity. Bisphosphonates (BP), pyrophosphate analogues ...
Source: Internal Medicine Journal - August 6, 2017 Category: Internal Medicine Authors: Oi Lin Lee, Noemi Horvath, Cindy Lee, Doug Joshua, Joy Ho, Jeff Szer, Hang Quach, Andrew Spencer, Simon Harrison, Peter Mollee, Andrew W. Roberts, Dipti Talaulikar, Ross Brown, Bradley Augustson, Silvia Ling, Wilfrid Jaksic, John Gibson, Anna Kalff, Anna Tags: Position Paper Source Type: research

The role of bone-targeted therapies for prostate cancer in 2017
Purpose of review: Bone-targeted agents (BTAs), such as zoledronic acid and denosumab, delay the occurrence of skeletal-related events (SREs) in metastatic prostate cancer (PCa) patients. Recently, several agents, such as abiraterone acetate, enzalutamide and radium-223, were approved for the treatment of metastatic castration-resistant PCa (mCRPC). These agents resulted in improved overall survival (OS), pain control and had positive effects on bone health. Combining BTAs to the newly approved agents demonstrates additional benefits that warrant a review of available evidence looking at appropriate combination therapies a...
Source: Current Opinion in Supportive and Palliative Care - August 3, 2017 Category: Palliative Care Tags: RENAL AND UROLOGICAL PROBLEMS: Edited by Fred Saad Source Type: research

Evaluation of mandibular bone after dental extraction in rats treated with antiresorptive drugs
Zoledronic acid (ZOL) and denosumab (Dmab) are commonly used to treat bone pathologies. Given that both drugs suppress bone metabolism, this study sought to compare their effect on bone repair after tooth extraction. (Source: Journal of Oral and Maxillofacial Surgery)
Source: Journal of Oral and Maxillofacial Surgery - August 3, 2017 Category: ENT & OMF Authors: Victor Lousan Do Nascimento Poubel, Diogo Lenzi Capella, Adair Roberto Soares Santos, M árcio Correa, Letícia Ruhland Correa, Elena Riet Correa Rivero Source Type: research

Zoledronic acid and bone cellular respiration
AbstractPhosphorescence O2 analyzer was used to measure calvarial bone cellular respiration (cellular mitochondrial O2 consumption) in Taylor Outbred mice in the presence and absence of zoledronic acid. This potent bisphosphonate inhibits osteoclast-mediated calcium resorption, and its effects on bone respiration have not been previously investigated. The change of O2 concentration with time was measured in closed vials containing phosphate-buffered saline (PBS), 5  mM glucose and 5–25 mg calvarial bone fragments, and it was complex fort = 0–30 h. Cyanide (specific inhibitor of cytochro...
Source: Journal of Bone and Mineral Metabolism - August 1, 2017 Category: Orthopaedics Source Type: research

Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia
This article is protected by copyright. All rights reserved (Source: Journal of Orthopaedic Research)
Source: Journal of Orthopaedic Research - August 1, 2017 Category: Orthopaedics Authors: Mumingjiang Yishake, Miersalijiang Yasen, Jiang Libo, Liu Wangmi, Xing Rong, Chen Qian, Lin Hong, Dong Jian Tags: Research Article Source Type: research

Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence
ConclusionsThe treatment of mCRPC was associated with significant cost. In the post-docetaxel setting, single fraction radiotherapy and enzalutamide were considered cost-effective in most studies. Generic ZA was the recommended bone-targeting therapy. (Source: PharmacoEconomics)
Source: PharmacoEconomics - July 29, 2017 Category: Health Management Source Type: research

Chronic infusion of zoledronic acid rises inflammatory markers in periodontium of rats
This study aims to evaluate inflammatory markers in periodontium of rats treated with zoledronic acid (ZA). (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)

Bisphosphonate-associated spontaneous osteonecrosis of maxilla: a case report
Bisphosphonate therapy can lead to late complications, such as osteonecrosis because of reduced activity of osteoclasts and changing in bone remodeling. Herein we present a case of a male patient, 47 years old, who was diagnosed with multiple myeloma and treated with zoledronic acid (4 mg intravenously monthly over 3 years). The patient presented to dental care with complaints of pain in the maxilla. On physical examination, exposed bone in the palatal region of the tooth 27 was observed. Biopsy was performed and devitalized bone confirmed. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - July 28, 2017 Category: ENT & OMF Authors: LAURA IZABEL LAMPERT BONZANINI, RI ÉLI ELIS SCHULZ, ELOISA BARBIERI SOLDERA, GABRIELA BARBIERI ORTIGARA, MÔNICA PAGLIARINI BULIGON, KÍVIA LINHARES FERRAZZO, JENIFER COLOMBELLI MIELKE Tags: CPP - Clinical Poster Presentation Source Type: research

Multiple myeloma associated oral amyloidosis: report of a case
In this report, we describe an original case of amyloidosis affecting the oral cavity of a 77-year-old male patient that was under chemotherapy and zoledronic acid treatment because of a previously diagnosed multiple myeloma. The patient demonstrated multiple asymptomatic nodules in the tongue with 3 weeks ’ duration that microscopically revealed a diffuse deposition of a homogeneous, eosinophilic material, which predominated around blood vessels and salivary gland acini. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - July 28, 2017 Category: ENT & OMF Authors: MILENA CORREIA DE PINHO, FELIPE PAIVA FONSECA, CLAUDIA JOFFILY PARAHYBA, ANA CRISTINA ALO NESRALLAH, BERNAR MONTEIRO BENITES, EDUARDO RODRIGUES FREGNANI Tags: CPP - Clinical Poster Presentation Source Type: research

Comparison of effects of zoledronic acid and clodronate on the bone structure: imaginologic and histologic study
The objective of this study was to compare, by means of histologic and imagiologic tools, the bone structure of mandibles of rats treated and not treated with bisphosphonates (BPs). 34 rats were divided in 3 groups: (1) 12 mandibles of rats treated with zoledronic acid; (2) 12 mandibles of rats treated with clodronate; (3) control group, 10 mandibles of rats that received saline solution. All specimens were exposed to cone beam computed tomography (CBCT). The images were analyzed to obtain the bone density (BD) in Hounsfield Units (HU), using the software OsiriX 7.0. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Or...
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - July 28, 2017 Category: ENT & OMF Authors: FELIPE MARTINS SILVEIRA, STEPHANIE JOANA ROMAN MARTELLI, ANA PAULA NEUTZLING GOMES, ANDR É RIBEIRO SCHINESTSCK, MELISSA FERES DAMIAN, ANA CAROLINA UCHOA VASCONCELOS Tags: RP - Research Poster Source Type: research

Immune cell profile of dental pulp in rats treated with zoledronic acid
The objective of this study was to characterize the pulp immune cell profile in the teeth of rats treated with Zoledronic Acid (ZA). For this Male Wistar rats (n=6) received 4 intravenous infusions of ZA (0.04, 0.20 or 1.00 mg/kg) or saline. In the 70th day, they were euthanized. The first right molar was microscopically examined (H&E, toluidine blue and immunohistochemistry for CD68, Tumor Necrosis Factor (TNF)- α, Interleukin(IL)-1β, Inducible Nitric Oxide Synthase (iNOS), Nuclear Factor kappa B (NFkB) and IL-18 binding protein (IL-18bp). (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)

Use of platelet-rich plasma in medication related osteonecrosis of jaw treatment: experimental study
Bone resection associated with platelet-rich plasma (PRP) is a proposal in management of medication related osteonecrosis of jaw (MRONJ), which has demonstrated clinical success in the symptomatic cases. The aim of this study was to evaluate the surgical treatment of MRONJ using PRP. 30 rats received intravenous zoledronic acid (35 μg/kg in 0.9% NaCl, for 8 weeks) and the upper right incisor extraction was performed to induce MRONJ. The surgical treatment was performed after the diagnosis of MRONJ. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - July 28, 2017 Category: ENT & OMF Authors: CAMILA LOPES CARDOSO, CL ÁUDIA CURRA, MARCOS MARTINS CURI, CAMILA DIONÍSIO ARGENTINO, OSNY FERREIRA JÚNIOR, SOLANGE DE OLIVEIRA BRAGA FRANZOLIN, ANDRÉIA APARECIDA DA SILVA Tags: RP - Research Poster Source Type: research

ZEST: Greater Improvements in Bone Mineral Density With Zoledronic Acid vs Switch From TDF in HIV-Infected Osteopenic Men on Stable TDF-Containing ART Over 2 Years
Conference Capsule - eGFR was significantly lower with zoledronic acid vs TDF switch, despite improvements in bone mineral density. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 28, 2017 Category: Infectious Diseases Source Type: research

Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature
ConclusionsMedical oncologists should be aware of renal adverse events for patients with advanced non-small cell lung cancer eligible for pemetrexed maintenance therapy. Suggestions for mitigating the risk for renal toxicities (dehydration, non-steroidal anti-inflammatory drugs and zoledronic acid, radiocontrast agents) during pemetrexed maintenance should be followed to enable early detection and management of this adverse event. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - July 28, 2017 Category: General Medicine Source Type: research

Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors
Publication date: Available online 21 July 2017 Source:European Geriatric Medicine Author(s): V. Gunmalm, N.R. Jørgensen, B. Abrahamsen, P. Schwarz Breast cancer (BC) is the most common cancer amongst women worldwide. Bone health is emerging as an important issue for BC survivors. In this literature study, we focus on agents for preventing bone loss in early non-metastatic estrogen receptor positive BC in treatment with aromatase inhibitors (AI) and to assess the evidence for antiresorptive treatment of bone loss in early non-metastatic breast cancer. We included randomized controlled trials (RCT's) comparing: (a) ...
Source: European Geriatric Medicine - July 28, 2017 Category: Geriatrics Source Type: research

Acute severe diarrhoea and hyponatremia after zoledronic acid infusion: an acute phase reaction.
We describe a case of acute watery diarrhoea complicated by severe hyponatremia and hypotension following ZA infusion. The patient needed intensive care for four days. To the best of our knowledge, this type of acute diarrhoea complicated by severe hyponatremia, following ZA infusion, is not reported so far. Strong temporal relation with ZA administration makes it the most likely cause. Furthermore, all laboratory and imaging parameters indicate that the secretory diarrhoea may be a component of acute phase reaction. According to World Health Organization (WHO) causality scale, ZA was a probable cause of acute watery diarr...
Source: Clinical Cases in Mineral and Bone Metabolism - July 27, 2017 Category: Orthopaedics Tags: Clin Cases Miner Bone Metab Source Type: research

The effects of zoledronic acid on ECG: a prospective study on patients with bone metastatic cancer.
CONCLUSION: There were no significant alterations in ECG in the acute period, indicated that ZA had no arrhythmia potential in the early period in patients with no underlying cardiac disease. However: patients receiving ZA should be monitored more closely because of the risk of arrhythmia which may ensue due to hypocalcemia, hypomagnesemia, or other chemotherapeutics. PMID: 28740523 [PubMed] (Source: Clinical Cases in Mineral and Bone Metabolism)
Source: Clinical Cases in Mineral and Bone Metabolism - July 27, 2017 Category: Orthopaedics Tags: Clin Cases Miner Bone Metab Source Type: research

Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer
We report the data for the secondary end point of disease-free survival (DFS). (Source: Journal of Surgical Research)
Source: Journal of Surgical Research - July 26, 2017 Category: Surgery Authors: Takashi Ishikawa, Kouhei Akazawa, Yoshie Hasegawa, Hirokazu Tanino, Jun Horiguchi, Daishu Miura, Mitsuhiro Hayashi, Norio Kohno Tags: Oncology Source Type: research

M4IDP, a zoledronic acid derivative, induces G1 arrest, apoptosis and autophagy in HCT116 colon carcinoma cells via blocking PI3K/Akt/mTOR pathway
This study also provides a better understanding of the antitumor effects and the underlying mechanisms of bisphosphonates in the field of CRC therapy. (Source: Life Sciences)
Source: Life Sciences - July 25, 2017 Category: Biology Source Type: research

Glucocorticoid sparing effect of zoledronic acid in sarcoid hypercalcemia
ConclusionZoledronic acid should be studied as a potential first-line agent for sarcoid hypercalcemia. Furthermore, disease-modifying effects of zoledronic acid in sarcoidosis should be investigated. (Source: Archives of Orthopaedic and Trauma Surgery)
Source: Archives of Orthopaedic and Trauma Surgery - July 19, 2017 Category: Orthopaedics Source Type: research

Bone Tissue Response Following Local Drug Delivery of Bisphosphonate Through Titanium Oxide Nanotube Implants in a Rabbit Model.
The objective of this study was to evaluate whether surface chemistry controlled TiO2 nanotube structures may serve as a local drug delivery system for zoledronic acid improving implant bone support. METHODS: Twenty-four screw-shaped Ti implants with surface chemistry controlled TiO2 nanotube structures were prepared and divided into a zoledronic acid-formatted test and a native control group. The implants were inserted into contralateral femoral condyles in 12 New Zealand White rabbits. Bone support was evaluated using resonance frequency analysis (RFA) and removal torque (RTQ), as well as histometric analysis follow...
Source: Journal of Clinical Periodontology - July 13, 2017 Category: Dentistry Authors: Kwon DH, Lee SJ, Wikesjö UME, Johansson PH, Johansson CB, Sul YT Tags: J Clin Periodontol Source Type: research

Bone targeted therapies in advanced breast cancer.
Abstract Bone targeted therapies are of increasing importance, not only for bone health in the clinical course of breast cancer, but recently also in the adjuvant setting as preventative, anticancer and prognosis-improving agents. It is well established that women with advanced breast cancer receive bisphosphonates or denosumab to prevent therapy-related osteoporosis. As many as 70% of these patients suffer from bone metastases and receive bone targeted agents in order to prevent skeletal related events (SREs), which are debilitating or diminish the quality of life. A number of trials provided guidance, identifyin...
Source: Swiss Medical Weekly - July 11, 2017 Category: General Medicine Authors: Biskup E, Cai F, Vetter M Tags: Swiss Med Wkly Source Type: research

Influence of bisphosphonates on the adherence and metabolism of epithelial cells and gingival fibroblasts to titanium surfaces
ConclusionBisphosphonates negatively affected the adhesion and metabolism of oral mucosal cells, and this effect was related to the type of bisphosphonate as well as to concentration and period of treatment.Clinical relevanceThe negative effects of bisphosphonates on oral mucosal cells can hamper the formation of an effective biological seal in osseointegrated implants. (Source: Clinical Oral Investigations)
Source: Clinical Oral Investigations - July 8, 2017 Category: Dentistry Source Type: research

Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer.
Authors: Jun JH PMID: 28682020 [PubMed - as supplied by publisher] (Source: Korean Journal of Ophthalmology : KJO)
Source: Korean Journal of Ophthalmology : KJO - July 7, 2017 Category: Opthalmology Tags: Korean J Ophthalmol Source Type: research

Role of zoledronic acid in oncolytic virotherapy: promotion of antitumor effect and prevention of bone destruction
This article is protected by copyright. All rights reserved. (Source: Cancer Science)
Source: Cancer Science - July 7, 2017 Category: Cancer & Oncology Authors: Yasuaki Yamakawa, Hiroshi Tazawa, Joe Hasei, Shuhei Osaki, Toshinori Omori, Kazuhisa Sugiu, Tadashi Komatsubara, Kouji Uotani, Tomohiro Fujiwara, Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara Tags: Original Article Source Type: research

Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein ‐2 and zoledronic acid
Abstract Tibial pseudarthrosis associated with Neurofibromatosis type 1 (NF1) is an orthopedic condition with consistently poor clinical outcomes. Using a murine model that features localized double inactivation of the Nf1 gene in an experimental tibial fracture, we tested the effects of recombinant human bone morphogenetic protein‐2 (rhBMP‐2) and/or the bisphosphonate zoledronic acid (ZA). Tibiae were harvested at 3 weeks for analysis, at which time there was negligible healing in un‐treated control fractures (7% union). In contrast, rhBMP‐2 and rhBMP‐2/ZA groups showed significantly greater union (87% and 93%, p 
Source: Journal of Orthopaedic Research - July 1, 2017 Category: Orthopaedics Authors: Nikita Deo, Tegan L Cheng, Kathy Mikulec, Lauren Peacock, David G Little, Aaron Schindeler Tags: Research Article Source Type: research

Role of ceramide in the aging-related decrease of cardiolipin content in the rat heart
AbstractCeramide accumulation and a decrease of cardiolipin level in cardiomyocytes are among the key reasons of mitochondrial dysfunction and the emergence of heart failure. Ceramide has a significant effect on cardiolipin metabolism, and, therefore, the aim of the present study was to assess the role of ceramide in the aging-related decrease of cardiolipin content in the rat heart. Young (sexually mature), adult, and old (3-, 12-, 24-, 30-, and 34-month-old) Wistar male rats were used in the study. A considerable decrease in the content of cardiolipin during aging was accompanied by accumulation of phosphatidic acid, a p...
Source: Advances in Gerontology - July 1, 2017 Category: Geriatrics Source Type: research

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma
This study defines a therapeutic strategy superior to the current standard of care that will reduce fractures for patients with MM. (Source: Blood)
Source: Blood - June 29, 2017 Category: Hematology Authors: McDonald, M. M., Reagan, M. R., Youlten, S. E., Mohanty, S. T., Seckinger, A., Terry, R. L., Pettitt, J. A., Simic, M. K., Cheng, T. L., Morse, A., Le, L. M. T., Abi-Hanna, D., Kramer, I., Falank, C., Fairfield, H., Ghobrial, I. M., Baldock, P. A., Little Tags: Multiple Myeloma, Lymphoid Neoplasia Source Type: research

Acute granulomatous interstitial nephritis and acute rejection in a kidney transplant recipient after zoledronic acid therapy - a case report and review of the literature.
CONCLUSION: To our knowledge, this is the first case of AGIN related to bisphosphonate zoledronate in a kidney transplant patient with consequent acute cellular rejection. In using intravenous zoledronate infusion in a kidney transplant recipient, we should be aware that it could potentially induce acute granulomatous tubulointerstitial nephritis and acute rejection.
. PMID: 28655390 [PubMed - as supplied by publisher] (Source: Clinical Nephrology)
Source: Clinical Nephrology - June 28, 2017 Category: Urology & Nephrology Authors: Avguštin N, Kovač D, Kojc N, Mlinšek G, Lindič J Tags: Clin Nephrol Source Type: research

GSE96075 Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer
Contributors : Shannon Murray ; Dhifaf Sarhan ; Andreas LundqvistSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensIn order to identify the processes altered in T regulatory cells (Treg) by Zoledronic acid (ZA), we examined RNA expression by RNA-seq in Treg treated with and without ZA. We identified gene expression alterations in ZA-treated Treg that were essential to Treg function. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - June 26, 2017 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Recurrence Factors in Giant Cell Tumors of the Spine.
We examined the rate of local recurrence of spinal GCTs and sought to identify recurrence factors in patients who underwent surgery. METHODS: Between 1995 and 2014, 94 mobile spine GCT patients were treated at our hospital, comprising 43 male and 51 female patients with an average age of 33.4 years. Piecemeal intralesional spondylectomy and total en bloc spondylectomy (TES) were performed. Radiotherapy was suggested for recurrent or residual GCT cases. Since denosumab was not available before 2014 in our country, only interferon and/or zoledronic acid was suggested. RESULTS: Of the 94 patients, four underwent con...
Source: Chinese Medical Journal - June 24, 2017 Category: General Medicine Authors: Ouyang HQ, Jiang L, Liu XG, Wei F, Yang SM, Meng N, Jiang P, Yu M, Wu FL, Dang L, Zhou H, Zhang H, Liu ZJ Tags: Chin Med J (Engl) Source Type: research